HK1211875A1 - Treating hearing loss - Google Patents

Treating hearing loss Download PDF

Info

Publication number
HK1211875A1
HK1211875A1 HK16100053.6A HK16100053A HK1211875A1 HK 1211875 A1 HK1211875 A1 HK 1211875A1 HK 16100053 A HK16100053 A HK 16100053A HK 1211875 A1 HK1211875 A1 HK 1211875A1
Authority
HK
Hong Kong
Prior art keywords
hearing loss
treating hearing
loss
treating
adolescents
Prior art date
Application number
HK16100053.6A
Other languages
English (en)
Chinese (zh)
Inventor
Albert Edge
Hideyuki Okano
Masato Fujioka
Kunio MIZUTARI
Original Assignee
Massachusetts Eye & Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Eye & Ear Infirmary filed Critical Massachusetts Eye & Ear Infirmary
Publication of HK1211875A1 publication Critical patent/HK1211875A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK16100053.6A 2012-09-07 2013-09-06 Treating hearing loss HK1211875A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261698475P 2012-09-07 2012-09-07
US201261698475P 2012-09-07
PCT/US2013/058446 WO2014039781A1 (en) 2012-09-07 2013-09-06 Treating hearing loss

Publications (1)

Publication Number Publication Date
HK1211875A1 true HK1211875A1 (en) 2016-06-03

Family

ID=50237627

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100053.6A HK1211875A1 (en) 2012-09-07 2013-09-06 Treating hearing loss

Country Status (7)

Country Link
US (3) US20150209367A1 (https=)
EP (2) EP2892506B1 (https=)
JP (4) JP2015527398A (https=)
AU (1) AU2013312358B2 (https=)
CA (1) CA2883896C (https=)
HK (1) HK1211875A1 (https=)
WO (1) WO2014039781A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
CA2883896C (en) * 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
TWI625332B (zh) * 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
US20180326080A1 (en) * 2015-10-27 2018-11-15 Purdue Research Foundation Polymer-based therapeutics for inductive browning of fat
CN109071450B (zh) * 2015-10-30 2021-06-22 帕珀莱恩医疗公司 二苯并氮杂卓化合物及其治疗耳部疾病和病症的用途
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
JP7033789B2 (ja) 2016-06-29 2022-03-11 オトノミー，インク． トリグリセリド耳用製剤とその使用
CN110248650A (zh) 2016-10-31 2019-09-17 霍夫耳科研究所 用于增强突触发生和神经突发生的方法
MX390370B (es) * 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
TW202034900A (zh) 2018-10-02 2020-10-01 美商頻率醫療公司 有關耳用治療劑之醫藥組成物及方法
KR20220007050A (ko) 2019-04-08 2022-01-18 프리퀀시 테라퓨틱스, 인크. 난청을 치료하기 위한 chir99021과 발프로산의 조합
TWI781536B (zh) 2021-02-26 2022-10-21 國立臺灣科技大學 藥物釋放組合物、其製造方法及其用途

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
USD309535S (en) 1987-03-30 1990-07-31 Chromcraft Furniture Corp. Chair
USD360535S (en) 1994-02-14 1995-07-25 Staffan Sjoberg Combined beach chair and beach mattress
EA002100B1 (ru) 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
US6635632B1 (en) 1996-12-23 2003-10-21 Athena Neurosciences, Inc. Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6683048B1 (en) 1997-04-10 2004-01-27 Mcgill University Compounds and methods for stimulating gene expression and cellular differentiation
KR100581199B1 (ko) 1998-06-19 2006-05-17 카이론 코포레이션 글리코겐 신타제 키나제 3의 억제제
AU4206200A (en) 1999-04-05 2000-10-23 Adherex Technologies Inc. Compounds and methods for stimulating beta-catenin mediated gene expression and differentiation
EP1237880B1 (en) 1999-12-17 2008-01-23 Novartis Vaccines and Diagnostics, Inc. Pyrazine based inhibitors of glycogen synthase kinase 3
CA2397543A1 (en) 2000-01-24 2001-07-26 Timothy Harrison Gamma-secretase inhibitors
GB0005251D0 (en) 2000-03-03 2000-04-26 Merck Sharp & Dohme Therapeutic compounds
WO2001070677A1 (en) 2000-03-20 2001-09-27 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
GB0008710D0 (en) 2000-04-07 2000-05-31 Merck Sharp & Dohme Therapeutic compounds
USD447031S1 (en) 2000-04-20 2001-08-28 Wang Keaun Oh Hand carry air tacker
KR100896489B1 (ko) 2000-07-11 2009-05-08 사운드 파마슈티칼스 인코퍼레이티드 내이에서 세포 재생 및 분화의 자극
US7399633B2 (en) 2000-10-27 2008-07-15 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
AU2002210747B2 (en) 2000-11-02 2006-06-01 Merck Sharp & Dohme Limited Sulfamides as gamma-secretase inhibitors
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US6483732B2 (en) 2000-12-13 2002-11-19 Koninklijke Philips Electronics N.V. Relational content addressable memory
GB0119152D0 (en) 2001-08-06 2001-09-26 Merck Sharp & Dohme Therapeutic agents
US7206639B2 (en) 2002-03-15 2007-04-17 Sarcos Investments Lc Cochlear drug delivery system and method
GB0209991D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209995D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0209997D0 (en) 2002-05-01 2002-06-12 Merck Sharp & Dohme Therapeutic agents
DE60328182D1 (de) 2002-05-01 2009-08-13 Merck Sharp & Dohme Heteroaryl substituierte spirocyclische sulfamide zur hemmung von gamma sekretase
GB0223038D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0223039D0 (en) 2002-10-04 2002-11-13 Merck Sharp & Dohme Therapeutic compounds
GB0225474D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
GB0225475D0 (en) 2002-11-01 2002-12-11 Merck Sharp & Dohme Therapeutic agents
WO2004083203A1 (en) 2003-03-13 2004-09-30 Vertex Pharmaceuticals Incorporated Compositions useful as protein kinase inhibitors
BRPI0408962A (pt) 2003-03-31 2006-04-04 Wyeth Corp inibidores sulfonamidas heterocìclicos contendo flúor- e trifluoroalquila da produção de beta amilóide e seus derivados
US20050019801A1 (en) 2003-06-04 2005-01-27 Curis, Inc. Stem cell-based methods for identifying and characterizing agents
GB0318447D0 (en) 2003-08-05 2003-09-10 Merck Sharp & Dohme Therapeutic agents
EP1660502A2 (en) 2003-08-28 2006-05-31 Choongwae Pharma Corporation MODULATION OF ß-CATENIN/TCF ACTIVATED TRANSCRIPTION
EP1667984B1 (en) 2003-09-24 2011-05-18 Merck Sharp & Dohme Ltd. Gamma-secretase inhibitors
GB0326039D0 (en) 2003-11-07 2003-12-10 Merck Sharp & Dohme Therapeutic agents
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
EP1727560B1 (en) 2004-01-27 2012-09-12 Kyowa Hakko Kirin Co., Ltd. Gastrointestinal proliferative factor and uses thereof
WO2005072793A1 (en) 2004-01-29 2005-08-11 The Charles Stark Draper Laboratory, Inc. Implantable drug delivery apparatus
AU2005217596B2 (en) 2004-02-23 2012-01-19 Eli Lilly And Company Anti-ABeta antibody
JP2006117536A (ja) * 2004-10-19 2006-05-11 Kyoto Univ 内耳の有毛細胞を誘導するための医薬
US9265933B2 (en) 2005-09-08 2016-02-23 Massachusetts Eye And Ear Infirmary Cochlear implants containing biological cells and uses thereof
US20090306045A1 (en) 2005-12-22 2009-12-10 Ira Mellman Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease
CA2644136A1 (en) 2006-02-27 2007-09-07 The Johns Hopkins University Cancer treatment with gamma-secretase inhibitors
US8158364B2 (en) * 2006-04-11 2012-04-17 The Board Of Regents Of The University Of Texas System Methods and compositions involving nucleotide repeat disorders
US8175269B2 (en) 2006-07-05 2012-05-08 Oracle International Corporation System and method for enterprise security including symmetric key protection
EP2094836B1 (en) 2006-11-15 2016-06-08 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2008071605A2 (en) 2006-12-15 2008-06-19 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
MX2010001754A (es) 2007-08-14 2010-05-14 Lilly Co Eli Derivados de azepina como inhibidores de gamma secretasa.
WO2009047163A1 (en) 2007-10-10 2009-04-16 F. Hoffmann-La Roche Ag Methods of treating inflammatory diseases
AU2009203776A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Use of a gamma-secretase inhibitor for treating cancer
EP2732819B1 (en) 2008-02-07 2019-10-16 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh-1 expression
KR20130097813A (ko) 2008-04-21 2013-09-03 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
GB2459910B (en) 2008-04-21 2010-03-31 Otonomy Inc Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
KR101534422B1 (ko) 2008-05-14 2015-07-09 오토노미, 인코포레이티드 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
WO2010060088A2 (en) * 2008-11-24 2010-05-27 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
US20110263580A1 (en) 2008-12-11 2011-10-27 Thomas Miller Method for treating alzheimer's disease and related conditions
US8609897B2 (en) 2009-02-06 2013-12-17 Merck Sharp & Dohme Corp. Trifluoromethylsulfonamide gamma secretase inhibitor
SI2493876T1 (sl) 2009-10-28 2014-04-30 Pfizer Inc. Derivati imidazola kot inhibitorji kazein-kinaze
CA134865S (en) 2010-02-11 2010-11-10 Hankook Tire Co Ltd Automobile tire
JP5889875B2 (ja) 2010-05-07 2016-03-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ アザインダゾール
CA2799207C (en) 2010-05-26 2019-03-26 Curna, Inc. Treatment of atonal homolog 1 (atoh1) related diseases by inhibition of natural antisense transcript to atoh1
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
RU2456356C1 (ru) 2011-04-29 2012-07-20 Борис Сергеевич Кустов Коллоидный раствор наносеребра и способ его получения
CA2883896C (en) * 2012-09-07 2023-03-07 Massachusetts Eye & Ear Infirmary Treating hearing loss
CA2884309A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methods and compositions for regenerating hair cells and/or supporting cells from differentiated cochlear cells or differentiated utricular cells by modulation of notch and cmyc activity
LT2970890T (lt) 2013-03-14 2020-07-10 The Brigham And Women`S Hospital, Inc. Kompozicijos ir būdai, skirti epitelinių kamieninių ląstelių padauginimui ir kultivavimui
US9572815B2 (en) 2013-03-15 2017-02-21 St. Jude Children's Research Hospital Methods and compositions of p27KIP1 transcriptional modulators
WO2015168149A2 (en) 2014-04-28 2015-11-05 Massachusetts Eye & Ear Infirmary Sensorineural hair cell differentiation
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
TWI625332B (zh) 2015-07-07 2018-06-01 美國禮來大藥廠 刻痕（ｎｏｔｃｈ）路徑傳訊抑制化合物
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
CN108779437A (zh) 2016-01-08 2018-11-09 麻省理工学院 分化的肠内分泌细胞和胰岛素产生细胞的制备
CN109219439B (zh) 2016-01-29 2022-09-20 马萨诸塞眼科耳科诊所 内耳支持细胞的扩增和分化及其使用方法
MX390370B (es) 2016-12-16 2025-03-20 Pipeline Therapeutics Inc Metodos para tratar la sinaptopatia coclear
WO2020112883A1 (en) 2018-11-30 2020-06-04 Massachusetts Eye And Ear Infirmary Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells

Also Published As

Publication number Publication date
EP2892506B1 (en) 2021-11-03
JP2015527398A (ja) 2015-09-17
JP2021038228A (ja) 2021-03-11
US20180369253A1 (en) 2018-12-27
EP3970725A1 (en) 2022-03-23
US20150209367A1 (en) 2015-07-30
US10898492B2 (en) 2021-01-26
AU2013312358A1 (en) 2015-03-19
EP3970725B1 (en) 2025-08-20
CA2883896C (en) 2023-03-07
EP2892506A4 (en) 2016-04-20
US20210299138A1 (en) 2021-09-30
AU2013312358B2 (en) 2018-08-09
CA2883896A1 (en) 2014-03-13
EP2892506A1 (en) 2015-07-15
JP2019172679A (ja) 2019-10-10
US12161647B2 (en) 2024-12-10
WO2014039781A1 (en) 2014-03-13
JP2022109965A (ja) 2022-07-28

Similar Documents

Publication Publication Date Title
HK1211875A1 (en) Treating hearing loss
EP2986140A4 (en) COMPOSITIONS, PROCESSES AND KIT FOR TREATMENT OF PETS
IL252952B (en) Diaminocarboxamide and diaminocarbonitrile converted pyrimidines, their compositions and methods of treatment
DK3628161T3 (da) Synergistiske bakterielle sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2014052836A3 (en) Methods and compositions for treating infection
EP2714099A4 (en) STERILIZED AZELLULAR / EXTRACELLULAR MATRIX COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP2836224A4 (en) COMPOSITIONS OF BIOZOOSE AND RELATED METHODS
MX2020002544A (es) Sales de glicopirrolato.
IL239901A0 (en) Converted pyrrolopyrimidine compounds and compositions and methods of treatment using them
MY173518A (en) Antimicrobial compounds and methods of making and using the same
BR112014029527A2 (pt) kit, métodos de tratamento de cabelo e método de texturização
BR112014004192A2 (pt) composição de tratamento de sementes, e, método de tratamento de sementes
HK1206393A1 (en) Compositions and methods for diagnosis and treatment of pervasive developmental disorder
EP2906178A4 (en) REMINERALIZING AND DESENSIBILIZING COMPOSITIONS, TREATMENTS AND METHOD OF PREPARATION
EP3077049A4 (en) Compositions and methods for treating vitiligo
DK2663095T3 (da) Høreapparat med fordelt bearbejdning i øreprop
EA201791538A1 (ru) Способ предотвращения или лечения потери слуха
MX367393B (es) Composiciones antifungicas para el tratamiento de piel y uñas.
ZA201409073B (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
BR112015002531A2 (pt) composição, método de tratamento de hipersensibilidade e uso de carbonato de cálcio.
WO2013009678A3 (en) Compositions and methods for the treatment of norovirus infection
BR112015013877A2 (pt) método, e, composição
BR112014008235A2 (pt) método de redução de toxicidade e/ou odor, e, composição
AU2013902122A0 (en) Ectoparasitic Treatment Method and Composition
ZA201406197B (en) Substituted diaminocarboxamide nand diaminocarbonitrile pyrimidines ,compositions thereof ,and methods of treatment therewith